Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), on-target/off-tumour toxicity; long-term B cell aplasia for CD19 CARs; secondary malignancy signal under surveillance. Here, CD19 is linked to neoplasm.